HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 
• By Francesca Bruce
  
"Uninformative" drug trials make pricing and reimbursement decisions harder, accoring to one senior HTA official. (Shutterstock)

More from Market Access

More from R&D